liquid biopsy Articles
-
Case Study B - Liquid Biopsy
X-ZELL is collaborating with Singapore General Hospital (SGH) and the National University Hospital Singapore (NUH) to explore how X-ZELL single-cell diagnostics may aid in the early detection of clinically significant prostate cancer in whole blood. The prospectively blinded, 400-patient multi-centre study officially commenced in 2020 and will lay the foundation for the launch of a commercially ...
By X-Zell Inc.
-
VisionGate’s New Website Illustrates its Mission to Save Lives through Early Detection of Lung Cancer
VisionGate, a Breakthrough Liquid-biopsy Technology Company, Leads the Battle Against Lung Cancer through Early Detection Technology with a Simple, Non-Intrusive Sputum Test. VisionGate wants you to live your life with peace of mind. That’s why we’ve launched a new website that makes it easy for you to learn more about our advanced lung cancer detection technology. Our new site ...
-
Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site
Summary Nanostics' clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked research institute in the Northeast US will now partner with Nanostics' by recruiting patients for the clinical validation study This partnership will ...
-
INOVIQ study validates the use of SubB2M as an aid in diagnosing malignant melanoma
Data from 144 tissue samples in the feasibility study demonstrated that SubB2M immunohistochemistry detected melanoma with 91% sensitivity and discriminated between malignant melanoma and benign skin lesions. SubB2M-based immunohistochemistry applications represent a new product opportunity for SubB2M in the $1.9b immunohistochemistry market. INOVIQ Ltd (ASX:IIQ) has successfully completed ...
By INOVIQ Ltd
-
New Findings from Universal DX: Through a Simple Blood Test, Our Body`s Gut Bacteria Can Help Detect Early-stage Colorectal Cancer
Company Presents Data at ESMO Congress Showing Link Between Microbiome Bacteria and Early Colorectal Cancer Detection (September 12, 2022) CAMBRIDGE, MA. - Universal Diagnostics (Universal DX), a bioinformatics and multi-omics company on a mission to transform cancer into a curable disease, today announced the results of a proof of principle study demonstrating that the analysis of microbiome ...
-
Human Microbiome Research Promotes Progress of Precision Medicine
A large part of bacterial, archaeal, viral, and fungal microbial taxa consists of the human microbiome. While many of these microorganisms are commensal, some are harmful to humans and many are symbiotic. Our livelihoods are strongly intertwined with the microbes we allocate our bodies with, regardless of whether their appearance is advantageous, insignificant, or harmful. Over the past few ...
By CD Genomics
-
Spanish Cancer Company Universal Dx to Commercialize Methylation Method for Lung Cancer Detection
NEW YORK - Spanish cancer research firm Universal Diagnostics is gearing up to commercialize a liquid biopsy test that applies methylation biomarkers to detect lung cancer, based on data presented at the International Association for the Study of Lung Cancer 2020 World Conference for Lung Cancer (WCLC) last month. The Seville-based firm also expects to release clinical data on its next ...
-
Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer
Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform. The study is supported in part by the Alberta Innovates AICE-Concepts Program with a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you